Carboprost Tromethamine Market - Global Industry Analysis

Global Carboprost Tromethamine Market: Overview

The global carboprost tromethamine market is expected to expand at a CAGR of 3.9% during the forecast period. Carboprost is a synthesized oxytocic prostalglandin. Carboprost tromethamine is also known as Hemabate, is a kind of prostaglandin that is used to treat excessive bleeding after childbirth in women and postpartum hemorrhage. It's also used as a contraceptive pill to trigger abortion by producing uterine contractions and progressive placental evacuation. The medication is given during the third and fifth months of pregnancy. It causes greater contractions by acting on the F receptor or the E2 receptor sites in the uterus muscles. As a result, the uterus's conception products are evacuated. Additionally, it enhances gastrointestinal stimulation, which can result in nausea and vomiting.

Report Scope:

Global Carboprost Tromethamine Market: Growth Factors

The global carboprost tromethamine market is growing at a rapid rate. A rise in the incidence of postpartum hemorrhage is the major factor that is driving the growth of the market for carboprost tromethamine. In the United States, postpartum hemorrhage is the greatest cause of maternal mortality on the day after birth, accounting for around 11% of all maternal fatalities. Also, as per the study conducted by Stanford Children Health, postpartum hemorrhage affects 1 in 100 to 5 in 100 women. It is more likely to occur in cesarean delivery. Thus, in order to reduce the mortality rate caused by postpartum hemorrhage in developed as well as developing countries, there is a rise in the demand for the use of carboprost tromethamine thereby fueling the market growth. Further, initiatives taken by the government regarding the use of carboprost tromethamine in rural areas are fostering the market growth. In addition to this, favorable support by regulatory bodies for the approval of the drug is also supporting the growth of the market. Moreover, the growing inclination towards the use of generic drugs and key market players involved in the production of generic drugs of carboprost tromethamine may have numerous opportunities for the growth of the global carboprost tromethamine market during the forecast period. For instance, in March 2021, Sunny Pharmtech Inc. revealed that their Carboprost Tromethamine Injection ANDA ("Abbreviated New Drug Application") is approved by the US FDA on March 26, 2021. However, serious adverse effects related to carboprost tromethamine administration, such as menstruation irregularities, breast soreness, and nausea is limiting the growth of the global carboprost tromethamine market.

The impact of the COVID-19 pandemic on the global carboprost tromethamine market was estimated low to moderate. This is due to the fully operational pharmaceutical sector during the pandemic period. Demand for pharmaceutical products for all the applications remained high, also, the fewer restrictions on transportation of pharmaceutical products maintained the revenue flow for the carboprost tromethamine market.

Global Carboprost Tromethamine Market: Segmentation

The global market for carboprost tromethamine is categorized based on type, application, and region. Based on region, the global market for carboprost tromethamine is bifurcated into 50 ML and below and more than 50 ML. The application segment of the market is segregated into personal care, pharmaceuticals, and others.

Global Carboprost Tromethamine Market: Regional Analysis

North America is likely to hold the largest share in the global carboprost tromethamine market. This is mainly attributed to the increasing demand for contraceptive pills and to treat severe bleeding after childbirth in the United States and Canada. Besides, the presence of major manufacturers in the region ensures the continuous use of carboprost tromethamine. Asia Pacific is projected to offer healthy growth opportunities for the expansion of the carboprost tromethamine market during the forecast period. The two biggest pharma manufacturing countries such as China and India are primarily supporting the growth of the market in the region. China is likely to remain the major revenue contributor in the region whereas, India is projected to showcase rapid growth during the forecast period.

Global Carboprost Tromethamine Market: Competitive Players

Major players functioning in the global carboprost tromethamine market include Pfizer, Blink Health, ChemScene, NEON LABORATORIES, and Universal Biologicals

Global Carboprost Tromethamine Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.